Nivolumab for EBV-related lymphomas and abnormal immune illnesses
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This trial tests nivolumab (an immune therapy) for people with EBV-positive lymphoma or EBV-driven immune/lymph conditions. It may help shrink tumors or control the disease when standard treatments have not worked or are not suitable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have lab-confirmed EBV-positive lymphoma or EBV-positive abnormal lymph/immune disease (a pathology or cytology test result).
- Your diagnosis must be one of the listed types (such as lymphomatoid granulomatosis, chronic active EBV disease, EBV-positive DLBCL, or certain EBV-related post-transplant conditions—solid organ transplant after is excluded).
- You must be at least 12 years old, and if you’re 12–17 you must meet the study weight and dosing safety rules (including discussing dosing safety if under 40 kg).
- You need to be able to recover from treatment: there must be enough time since prior anti-cancer therapy (at least 2 weeks) and enough time since stem cell transplant/DLI (at least 100 days).
- Your blood counts and organ/liver/kidney tests must meet the study thresholds, and you must have measurable or evaluable disease.
- You must be willing to provide tumor tissue for study tests (archival tissue is required; if not enough, a new pre-treatment biopsy may be needed).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests a lab-made immune cell treatment (cytotoxic T-lymphocytes) for certain lymphomas and related diseases that test positive for the Epstein-Barr virus (EBV). It may help your immune system attack EBV-infected cancer cells, especially after the cancer has come back or when transplant isn’t suitable.
This trial tests two drugs (pomalidomide and nivolumab) in people with cancers caused by viruses. The goal is to see if this combination can shrink or control tumors that haven't responded to standard therapies.
This study tests how well the immunotherapy medicine nivolumab works—either by itself or combined with other immune-boosting drugs—for people with advanced basal cell carcinoma that can’t be removed by surgery or has spread. It’s also looking at what to do if the cancer grows again after an earlier immunotherapy.
This Phase 1 study tests an immune-cell therapy made to recognize EBV (a common virus) in people whose lymphoma contains EBV. It may help control EBV-driven cancers, especially when standard treatment isn’t working or can’t be used.
This trial tests an investigational mRNA vaccine (WGc-043) that aims to help your immune system fight EBV-positive lymphoma cells. If you have tried standard treatments and your lymphoma is still active, this vaccine might offer a new option.
This study tests a combination of four drugs (an immunotherapy called a PD-1 inhibitor, an antiviral drug called tenofovir, and two other targeted therapies) for people whose EBV-related lymphoma has come back or not improved after treatment. The goal is to see if this combination can control the disease and help patients live longer.
Hear when a new Epstein-Barr Virus Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.